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Abstract
Background: Large randomised clinical trials and systematic reviews substantiate that tamoxifen
is ineffective in improving survival of patients with hepatocellular carcinoma (HCC). However, a
recent report suggested that the drug might prolong survival among patients with well preserved
liver function. The aim of this paper is to validate this hypothesis.
Methods: We used the updated database of the phase 3 randomised CLIP-1 trial that compared
tamoxifen with supportive therapy. Primary endpoint was overall survival. Treatment arms were
compared within strata defined according to the Okuda stage and the CLIP-score. Survival
differences were tested by the Log-rank test.
Results: Tamoxifen was not effective in prolonging survival in Okuda I-II subgroup (p = 0.501).
Median survival times were equal to 16.8 (95%CI 12.7–18.5) months for tamoxifen and 16.8 (95%CI
13.5–22.4) months for the control arms; 1-year survival probabilities were equal to 58.8% (95%CI
51.7–65.8) and 59.4 (95%CI 52.5–66.2), respectively. Similar results were observed in the better
CLIP subgroup (score 0/1), without evidence of difference between the two treatment arms (p =
0.734). Median survival times were equal to 29.2 (95%CI 20.1–36.4) months with tamoxifen and
29.0 (95%CI 23.3–35.2) months without; 1-year survival probabilities were equal to 80.9% (95%CI
72.5–89.3) with tamoxifen and 77.1% (95%CI 68.6–85.7) for the control arm.
Conclusion: The recent suggestion that tamoxifen might be effective in the subgroup of patients
with better prognosis is not supported by a reanalysis of the CLIP-1 trial. Tamoxifen should no
longer be considered for the treatment of HCC patients and future trials of medical treatment
should concentrate on different drugs.
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Background
At the end of '90, large randomised clinical trials showed
the ineffectiveness of tamoxifen in the treatment of hepa-
tocellular carcinoma (HCC) both in advanced [1,2] and
potentially curable patients [3]. Since then many reviews
repeatedly asserted there was no evidence of any effect of
tamoxifen in improving survival of HCC patients [4-9].
Recently, the lack of a survival advantage was further con-
firmed by a French trial with 420 HCC patients randomly
assigned tamoxifen or supportive care alone [10]. This
trial added an important piece of information because
tamoxifen was found ineffective also in a HCC population
with a high prevalence of alcohol-related liver cirrhosis.
However, following a post-hoc unplanned subgroup anal-
ysis, the Authors suggested that tamoxifen might be effec-
tive in a population of patients without major hepatic
insufficiency, i.e. those with Okuda stage I or II, and that
new trials on tamoxifen are still warranted.
The aim of this paper is to externally validate the hypoth-
esis of Barbare et al. [10] using the updated data of the
CLIP-1 randomised trial [3].
Methods
The methods of the CLIP-1 trial have been detailed else-
where [1]. Brief information is given below.
CLIP-1 multicenter randomised trial had a pragmatic
approach with large and simple inclusion criteria: all
patients with a life expectancy longer than three months
and diagnosed less than two years before were eligible for
the study. Differently from other studies, this trial was not
limited to patients with advanced disease, thus we had the
opportunity to assess the possible efficacy of treatment
with tamoxifen even in potentially curable subjects [3].
Patients were centrally randomised either to tamoxifen
(40 mg/day) or supportive therapy using a minimization
procedure with center, evidence of disease at entry and
time from HCC diagnosis as stratification variables. Over-
all 496 subjects entered the study from 30 Italian institu-
tions and 477 were evaluable for the analysis, 237
assigned to the tamoxifen arm, and 240 to the control
arm.
Overall survival was the only endpoint of the trial and
analyses were performed according to an intention-to-
treat basis. Survival curves were drawn by the Kaplan-
Meier method and compared by the logrank test.
CLIP score was estimated as reported before [11,12], using
Child-Pugh stage, tumor morphology, alpha fetoprotein
(AFP) and portal vein thrombosis as score components.
The hypothesis to be tested was that tamoxifen might be
effective in patients with better prognosis, thus, according
to the original study [10], two subgroups of the Okuda
stage were derived (I/II and III/unknown). Similarly two
subgroups of the CLIP score were obtained combining
together the patients at better prognosis (scores 0 or 1)
and at worse prognosis (scores equal to or greater than 2
or unknown).
Results
Distributions of baseline variables by treatment arm are
reported in Table 1, for Okuda subgroups, and Table 2, for
CLIP subgroups.
Table 1: Distributions of baseline variables by treatment arm, according to prognostic Okuda subgroups
Okuda category I-II III or unknown
Tamoxifen (n = 189) Control (n = 196) Tamoxifen (n = 48) Control (n = 44)
Median (range) age, years 66 (39–91) 67 (42–84) 62 (37–86) 66 (31–80)
Men 133 (70.4) 144 (73.5) 36 (75.0) 39 (88.6)
Evidence of disease at entry 178 (94.2) 184 (93.9) 40 (83.3) 39 (88.6)
Interval between diagnosis and entry
0–6 months 150 (79.4) 161 (82.1) 44 (91.7) 38 (86.7)
7–12 months 20 (10.6) 15 (7.7) 1 (2.1) 4 (9.1)
13–24 months 19 (10.1) 20 (10.2) 6 (6.3) 2 (4.6)
Child-Pugh category
A 90 (47.6) 98 (50.0) 25 (52.1) 20 (45.6)
B 82 (43.4) 75 (38.3) 13 (27.1) 11 (25.0)
C 17 (9.0) 23 (11.7) 9 (18.8) 12 (27.3)
unknown 0 (0.0) 0 (0.0) 1 (2.1) 1 (2.3)
Locoregional treatment
Surgery 11 (5.8) 12 (6.1) 7 (14.6) 3 (6.8)
Percutaneous Ethanol Injection 61 (32.3) 72 (36.7) 3 (6.3) 6 (13.6)
Transarterial chemoembolization 31 (16.4) 33 (16.8) 11 (22.9) 5 (11.4)
none 86 (45.5) 79 (40.3) 27 (56.3) 30 (68.2)BMC Cancer 2006, 6:196 http://www.biomedcentral.com/1471-2407/6/196
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Overall baseline variables were well balanced between the
two treatment arms. As expected, more potentially cura-
tive treatments (surgery or percutaneous ethanol injec-
tion) were observed in the subgroup with the better
prognosis. Less patients were classified in the better sub-
group with the CLIP score than with the Okuda score.
Kaplan-Meier survival curves for treatment arms, sepa-
rately by Okuda subgroups are reported in Figure 1 (score
I/II) and 2 (score III/unknown). In both cases tamoxifen
was not effective (p = 0.501 and p = 0.650, respectively).
In the first subgroup median survival times was equal to
16.8 (95%CI 12.7–18.5) months for tamoxifen and 16.8
(95%CI 13.5–22.4) months for the control arms; 1-year
survival probabilities were equal to 58.8% (95%CI 51.7–
65.8) and 59.4 (95%CI 52.5–66.2), respectively. Of
course, in patients with Okuda stage III or unknown,
prognosis was much worse, median survival times being
equal to 8.9 (95%CI 5.5–14.5) months for tamoxifen and
13.1 (95%CI 6.0–28.0) months for control; 1-year sur-
vival probabilities were equal to 42.6% (95%CI 28.4–
56.7) with tamoxifen and 50.8% (95%CI 35.7–65.8)
without it.
Kaplan-Meier survival curves for treatment arms, sepa-
rately by CLIP subgroups are reported in Figure 3 (score 0/
Kaplan-Meier estimated survival curves by treatment arm,  according to Okuda subgroups III/unknown Figure 2
Kaplan-Meier estimated survival curves by treatment arm, 
according to Okuda subgroups III/unknown.
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Table 2: Distributions of baseline variables by treatment arm, according to prognostic CLIP subgroups
Clip category 0–1 2–6 or unknown
Tamoxifen (n = 85) Control (n = 94) Tamoxifen (n = 152) Control (n = 146)
Median (range) age (years) 66 (37–91) 66 (31–80) 65 (39–86) 67 (42–84)
Men 57 (67.1) 68 (72.3) 112 (73.7) 115 (78.8)
Evidence of disease at entry 77 (90.6) 86 (91.5) 141 (92.8) 137 (93.8)
Interval between diagnosis and entry
0–6 months 85 (100.0) 94 (100.0) 109 (71.7) 105 (71.9)
7–12 months 0 (0.0) 0 (0.0) 21 (13.8) 19 (13.0)
13–24 months 0 (0.0) 0 (0.0) 22 (14.5) 22 (15.1)
Child-Pugh category
A 62 (72.9) 67 (71.3) 53 (34.9) 51 (34.9)
B 23 (27.1) 27 (28.7) 72 (47.4) 59 (40.4)
C 0 (0.0) 0 (0.0) 26 (42.6) 35 (24.0)
unknown 0 (0.0) 0 (0.0) 1 (0.7) 1 (0.7)
Locoregional treatment
Surgery 10 (11.8) 10 (10.6) 8 (5.3) 5 (3.4)
Percutaneous Ethanol Injection 34 (40.0) 46 (48.9) 30 (19.7) 32 (21.9)
Transarterial chemoembolization 18 (21.2) 17 (18.1) 24 (15.8) 21 (14.4)
none 23 (27.1) 21 (22.3) 90 (59.2) 88 (60.3)
Kaplan-Meier estimated survival curves by treatment arm,  according to Okuda subgroups I/II Figure 1
Kaplan-Meier estimated survival curves by treatment arm, 
according to Okuda subgroups I/II.
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1) and 4 (score ≥2/unknown). Once again no statistically
significant differences were found between the two treat-
ment arms (p = 0.734) in the subgroup at better prognosis
and (p = 0.286) in the subgroup at worse prognosis). In
the first subgroup median survival times were equal to
29.2 (95% CI 20.1–36.4) months with tamoxifen and
29.0 (95% CI 23.3–35.2) months without it; 1-year sur-
vival probabilities were equal to 80.9% (95% CI 72.5–
89.3) with tamoxifen and 77.1% (95% CI 68.6–85.7) for
the control arm. Prognosis was worse in patients with
CLIP score >1 or unknown, median survival times being
equal to 8.4 (95% CI 6.2–11.9) months for tamoxifen and
9.1 (95% CI 6.6–13.8) months for control; 1-year survival
probabilities were equal to 41.1% (95% CI 33.2–49.0)
with tamoxifen and 45.5% (95%CI 37.4–53.6) without.
Discussion
In this paper we report a failed attempt to validate the Bar-
bare's hypothesis [10] that tamoxifen might be effective in
patients with better prognosis and confirm the previous
evidence that there is no survival advantage for treating
HCC patients with tamoxifen in addition to supportive
therapy.
Because of the broad eligibility criteria applied in the
CLIP-1 trial, we had already tested possible survival differ-
ences within subgroups defined by locoregional treatment
[3]. Because of the strict correlation between prognosis
and locoregional treatment, the present lack of signifi-
cance was expected.
We also tested the same hypothesis in subgroups defined
according to the CLIP score, that currently is the most
widely accepted and validated prognostic score for HCC
[11,12]. CLIP scores 0 and 1 definitely identified patients
without major hepatic insufficiency better than Okuda
score (Figures 1a and 2a), but once again no evidence of
tamoxifen effectiveness was found.
Our results substantiate the criticism against subgroup
analyses, even more urgently when they are not previously
planned. In multiple subgroup analyses both more false
negative results, due to the smaller size of the groups, and
more false positive results, due to multiple comparisons,
are expected. Exploring data in search for differences pos-
sibly depending on certain baseline characteristics may be
acceptable on its own, but subgroup findings must not be
over-interpreted [13]. Although the power is usually lim-
ited, only statistical tests of interaction should be per-
formed rather than subgroup-specific tests. Anyway, the
interpretation strictly depends on whether findings are
biologically plausible, how many analyses are done,
whether they are planned ahead and how much strong is
the statistical evidence, still being aware that most sub-
group claims tend to exaggerate the truth [13,14].
Often, it is enough to correct for multiple testing so that
results are no more statistically significant and conclu-
sions not sounded; as would have been the case in the trial
recently reported by Barbare et al [10].
Although Barbare et al. discussed their findings must be
regarded with great caution, their conclusion was that new
trials are warranted in the specific population without
major hepatic insufficiency. That conclusion brought
about this report, but we failed to substantiate it.
Kaplan-Meier estimated survival curves by treatment arm,  according to CLIP subgroups >1/unknown Figure 4
Kaplan-Meier estimated survival curves by treatment arm, 
according to CLIP subgroups >1/unknown.
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Kaplan-Meier estimated survival curves by treatment arm,  according to CLIP subgroups 0/1 Figure 3
Kaplan-Meier estimated survival curves by treatment arm, 
according to CLIP subgroups 0/1.
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Conclusion
In conclusion, we believe that the story of tamoxifen in
HCC was definitively written; to date, neither further trials
are warranted with this drug in HCC nor any use in clini-
cal practice should be considered because of its clear lack
of efficacy.
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